# Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT01308567** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1168 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Cabazitaxel (XRP6258)
- **DRUG:** Docetaxel (XRP6976)
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01308567
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05-05
- **Primary completion:** 2015-09
- **Final completion:** 2018-05
- **Target enrollment:** 1168 (ACTUAL)
- **Last updated:** 2019-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01308567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01308567, "Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01308567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*